Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing recombinant vaccines using its Virus-Like Particle (VLP) platform. Key product targets include seasonal and pandemic influenza (H1N1, H5N1) and Respiratory Syncytial Virus (RSV). The company operates a joint venture in India (CPL Biologicals) with Cadila Pharmaceuticals.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue | $0.8 million | $0.1 million |
| Net Loss | $(7.5) million | $(10.3) million |
| Net Loss Per Share | $(0.07) | $(0.10) |
| Operating Expenses | $8.3 million | $11.6 million |
| Cash & Cash Equivalents | $8.4 million | $14.6 million (end of period) |
| Short-Term Investments | $15.6 million | $23.6 million (end of period) |
| Total Assets | $70.1 million | $74.8 million (Dec 31, 2010) |
| Working Capital | $17.8 million | N/A |
Note: Revenue for Q1 2011 is derived primarily from services performed under a contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS BARDA).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $0.7 million (658%) compared to Q1 2010, driven by the commencement of the HHS BARDA contract awarded in February 2011.
- Reduced Net Loss: Net loss decreased by $2.9 million (28%) year-over-year, primarily due to a $3.6 million reduction in Research and Development (R&D) expenses.
- R&D Expense Reduction: R&D spending dropped from $9.0 million to $5.4 million, attributed to lower outside testing costs and reduced clinical trial spending for H1N1 and seasonal influenza candidates.
- Other Income/Expense: Total other income decreased by $1.1 million, largely due to a change in the fair value of warrant liability which shifted from a $1.1 million gain in 2010 to a $0.1 million expense in 2011.
- Investing Activities: Net cash provided by investing activities turned positive ($8.0 million) due to proceeds from maturities of short-term investments, contrasting with a significant cash outflow in the prior year.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management believes it has adequate capital to operate for at least the next twelve months based on current cash ($8.4 million), short-term investments ($15.6 million), anticipated HHS BARDA revenue, and proceeds from its At Market Issuance Sales Agreement (ATM). However, additional capital will be required for future clinical development and commercialization.
Key Developments:
- HHS BARDA Contract: Awarded a contract valued at up to $179 million ($97 million base + $82 million option) for the development of seasonal and pandemic influenza vaccines.
- LG Life Sciences License: Entered a licensing agreement in February 2011 for influenza vaccine development in South Korea and emerging markets.
- Leadership Change: In April 2011 (subsequent event), CEO Dr. Rahul Singhvi was terminated without cause, and Executive Chairman Stanley Erck was appointed as the new President and CEO.
Risks and Contingencies:
- Liquidity Risk: Continued losses and dependence on external financing (equity offerings, government contracts) pose a risk. Failure to secure funding could force delays or elimination of R&D programs.
- Contractual Obligations: The company has a master services agreement with Cadila requiring a minimum spend of $7.5 million by March 2012. As of March 31, 2011, only $0.1 million had been spent, creating a potential shortfall obligation.
- Legal Proceedings: Active lawsuits against two former directors for the collection of defaulted notes totaling $1.572 million.
- Regulatory and Clinical Risk: No vaccine candidates have received regulatory approval. Clinical trials may fail to demonstrate safety or efficacy, and manufacturing scale-up presents significant challenges.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $9.0 million quarterly operating cash burn against the $24 million total liquid assets (cash + short-term investments).
- Cadila Shortfall: Assess the financial impact of the potential $7.4 million shortfall in the Cadila master services agreement and the company's ability to negotiate terms.
- HHS BARDA Performance: Monitor the company's ability to meet performance milestones under the HHS BARDA contract to ensure continued revenue recognition.
- ATM Utilization: Track the pace of share sales under the At Market Issuance Sales Agreement and the resulting dilution to existing shareholders.
- Legal Recovery: Follow the status of litigation against former directors to determine the likelihood of recovering the $1.572 million in defaulted notes.